J.-P. Bronowicki
About
J.-P. Bronowicki is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, J.-P. Bronowicki has authored 30 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 9 papers in Epidemiology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J.-P. Bronowicki's work include Hepatitis C virus research (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Liver Disease Diagnosis and Treatment (5 papers). J.-P. Bronowicki is often cited by papers focused on Hepatitis C virus research (15 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Liver Disease Diagnosis and Treatment (5 papers). J.-P. Bronowicki collaborates with scholars based in France, United States and Germany. J.-P. Bronowicki's co-authors include Christos N. Papandreou, Lucy Dagher, Stephanie Heldner, Seung Kew Yoon, F. Poordad, Keiko Nakajima, Arun J. Sanyal, Riccardo Lencioni, Laura Ladrón de Guevara and Tadatoshi Takayama and has published in prestigious journals such as Journal of Hepatology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.
In The Last Decade
J.-P. Bronowicki
29 papers receiving 439 citations
Peers
J.-P. Bronowicki
Isabelle Ollivier France
Guosheng Yuan China
Chie Tatsumi Japan
M.T. Tartaglione Italy
Amr El Fouly Egypt
Jing‐Houng Wang Taiwan
Takayoshi Oikawa Japan
Christie Perelló Spain
Taito Fukushima Japan
Matthias Dollinger Germany
Citations per year, relative to J.-P. Bronowicki J.-P. Bronowicki (= 1×)
peers
Isabelle Ollivier
Countries citing papers authored by J.-P. Bronowicki
Since
Specialization
Citations
This map shows the geographic impact of J.-P. Bronowicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-P. Bronowicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-P. Bronowicki more than expected).
Fields of papers citing papers by J.-P. Bronowicki
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J.-P. Bronowicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-P. Bronowicki. The network helps show where J.-P. Bronowicki may publish in the future.
Co-authorship network of co-authors of J.-P. Bronowicki
This figure shows the co-authorship network connecting the top 25 collaborators of J.-P. Bronowicki. A scholar is included among the top collaborators of J.-P. Bronowicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-P. Bronowicki. J.-P. Bronowicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bronowicki, J.-P., Patrick Miailhes, Denis Ouzan, et al.. (2022). An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir–grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study). Health Science Reports. 6(1). e619–e619.
2.
Laugel, Elodie, Cédric Hartard, Hélène Jeulin, et al.. (2020). Full‐length genome sequencing of RNA viruses—How the approach can enlighten us on hepatitis C and hepatitis E viruses. Reviews in Medical Virology. 31(4). e2197–e2197.
3.
Baère, T. de, Marc Pracht, Y. Rolland, et al.. (2020). PH-0159: NANORAY-103: Phase I/II trial of NBTXR3 activated by SBRT in patients with HCC and liver metastases. Radiotherapy and Oncology. 152. S74–S75.
4.
Pracht, Marc, É. Chajon, Y. Rolland, et al.. (2019). Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis. Annals of Oncology. 30. v291–v291.
5.
Berger, Sibel, Hélène Jeulin, Mouni Bensenane, et al.. (2018). Molecular features of Hepatitis E Virus circulation in environmental and human samples. Journal of Clinical Virology. 103. 63–70.
6.
Hézode, Christophe, Victor de Lédinghen, G. Haour, et al.. (2018). Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience. Journal of Hepatology. 68. S264–S264.
7.
Hézode, Christophe, Valériane Leroy, Isabelle Rosa, et al.. (2017). Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus Genotype 3 Infection. Journal of Hepatology. 66(1). S299–S300.
8.
Kudo, Masatoshi, Riccardo Lencioni, Jorge A. Marrero, et al.. (2016). Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational study. Liver International. 36(8). 1196–1205.
9.
Ayav, Ahmet, et al.. (2015). CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1. European Journal of Radiology. 85(1). 103–112.
10.
Merle, Philippe, G Pelletier, François Habersetzer, et al.. (2015). P1334 : A multicentre, randomised, open-label study comparing the efficacy and safety of two doses of Doxorubicin TransdrugTM to best standard of care in patients with advanced Hepatocellular Carcinoma (HCC) after sorafenib. The relive study. Journal of Hepatology. 62. S856–S857.
11.
Forns, Xavier, E. Läwitz, Stefan Zeuzem, et al.. (2014). O13 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIAL. Journal of Hepatology. 60(1). S6–S7.
12.
Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2013). 1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY. Journal of Hepatology. 58. S498–S498.
13.
Lencioni, Riccardo, Masatoshi Kudo, J.-P. Bronowicki, et al.. (2012). First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. International Journal of Clinical Practice. 66(7). 675–683.
14.
Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6.
15.
Mathurin, Philippe, Lluı́s Castells, G. Bodoky, et al.. (2012). 1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE. Journal of Hepatology. 56. S399–S400.
16.
Zarski, Jean‐Pierre, Valériane Leroy, M. Maynard-Muet, et al.. (2009). 42 A NOVEL VECTORIZED HCV THERAPEUTIC VACCINE (TG4040): RESULTS OF A PHASE I STUDY IN NAIVE PATIENTS CHRONICALLY INFECTED BY HCV. Journal of Hepatology. 50. S18–S18.
17.
Doffoël, M, Franck Bonnetain, Armand Abergel, et al.. (2008). Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). European Journal of Cancer. 44(4). 528–538.
18.
Watelet, J, et al.. (2002). Comparison of surgery and chemotherapy in alveolar echinococcosis. Journal of Hepatology. 36. 165–165.
19.
Renou, Christophe, Philippe Halfon, Stanislas Pol, et al.. (2002). Histological features and HLA class II alleles in HCV chronically infected patients with persistently normal alanine aminotransferase levels. Journal of Hepatology. 36. 169–170.
20.
Venard, Véronique, et al.. (2000). Hepatitis B virus X gene variability in French-born patients with chronic hepatitis and hepatocellular carcinoma. Journal of Medical Virology. 62(2). 177–184.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Isabelle Ollivier Breakdown of academic impact, for papers by Guosheng Yuan Breakdown of academic impact, for papers by Chie Tatsumi Breakdown of academic impact, for papers by M.T. Tartaglione Breakdown of academic impact, for papers by Amr El Fouly Breakdown of academic impact, for papers by Jing‐Houng Wang Breakdown of academic impact, for papers by Takayoshi Oikawa Breakdown of academic impact, for papers by Christie Perelló Breakdown of academic impact, for papers by Taito Fukushima Breakdown of academic impact, for papers by Matthias Dollinger